ALNY,MYGN Stock Price and Quote

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -3.58
Percentage change -1.22	%

Peers: VRTX REGN BMRN BIIB IONS SRPT ARWR NTLA CRSP EDIT

| Held by: VTI VO VXF VUG VOT IBB IWP XBI CGGR IWR

Index	-	P/E	-	EPS (ttm)	-2.09	Insider Own	4.39%	Shs Outstand	130.31M	Perf Week	1.98%
Market Cap	37.68B	Forward P/E	154.49	EPS next Y	1.87	Insider Trans	-2.24%	Shs Float	124.67M	Perf Month	19.44%
Income	-269.70M	PEG	-	EPS next Q	-0.67	Inst Own	96.25%	Short Float	2.53%	Perf Quarter	15.33%
Sales	2.35B	P/S	16.05	EPS this Y	62.19%	Inst Trans	3.53%	Short Ratio	3.16	Perf Half Y	24.42%
Book/sh	0.89	P/B	326.24	EPS next Y	326.92%	ROA	-6.71%	Short Interest	3.15M	Perf Year	92.36%
Cash/sh	20.19	P/C	14.32	EPS next 5Y	-	ROE	-	52W Range	146.79 - 304.39	Perf YTD	22.82%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.11%	ROI	-9.95%	52W High	-5.06%	Beta	0.19
Dividend TTM	-	Quick Ratio	2.98	Sales past 5Y	63.53%	Gross Margin	86.01%	52W Low	96.88%	ATR (14)	11.88
Dividend Ex-Date	-	Current Ratio	3.04	EPS Y/Y TTM	21.16%	Oper. Margin	-4.91%	RSI (14)	62.52	Volatility	1.46% 3.28%
Employees	2230	Debt/Eq	23.58	Sales Y/Y TTM	17.21%	Profit Margin	-11.49%	Recom	1.74	Target Price	324.54
Option/Short	Yes / Yes	LT Debt/Eq	22.47	EPS Q/Q	15.21%	Payout	-	Rel Volume	0.61	Prev Close	292.58
Sales Surprise	1.55%	EPS Surprise	50.56%	Sales Q/Q	20.20%	Earnings	May 01 BMO	Avg Volume	995.45K	Price	289.00
SMA20	6.85%	SMA50	11.96%	SMA200	10.72%	Trades		Volume	614,991	Change	-1.22%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-31-25	Initiated	Redburn Atlantic	Buy	$353
Mar-24-25	Upgrade	JP Morgan	Neutral → Overweight	$280 → $328
Nov-12-24	Downgrade	Wolfe Research	Peer Perform → Underperform
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-16-24	Upgrade	Goldman	Neutral → Buy	$198 → $370
Feb-16-24	Downgrade	Goldman	Buy → Neutral	$173
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-08-23	Initiated	Wells Fargo	Equal Weight	$171
Dec-08-23	Initiated	Wells Fargo	Equal Weight
Oct-11-23	Downgrade	Oppenheimer	Outperform → Perform
Sep-29-23	Initiated	Raymond James	Outperform	$208
May-05-23	Upgrade	BMO Capital Markets	Market Perform → Outperform	$200 → $250
Apr-26-23	Initiated	SMBC Nikko	Neutral	$220
Mar-21-23	Initiated	Bernstein	Outperform	$243
Jan-18-23	Initiated	Canaccord Genuity	Buy	$310
Sep-09-22	Resumed	Morgan Stanley	Equal-Weight	$222
Jul-13-22	Initiated	Cantor Fitzgerald	Neutral	$175
Jun-27-22	Downgrade	Guggenheim	Buy → Neutral
Jun-07-22	Initiated	William Blair	Outperform
Apr-25-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$210 → $178

Show Previous Ratings

May-20-25 09:00AM	Alnylam Issues 2024 Corporate Responsibility Report (Business Wire)
May-19-25 07:25PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
May-17-25 05:50AM	AMVUTTRA (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B (Business Wire)
May-13-25 10:18PM	Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term (Insider Monkey)
May-12-25 07:00AM	Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress (Business Wire) +7.58%
09:35AM	Loading…
May-08-25 09:35AM	Q1 2025 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents) -6.58%
04:00AM	Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications (Pharma Voice)
03:31AM	Vir Biotechnology Inc (VIR) Q1 2025 Earnings Call Highlights: Navigating Challenges with ... (GuruFocus.com)
May-07-25 07:17PM	Tracking Baillie Gifford's 13F Portfolio - Q1 2025 Update (Seeking Alpha)
04:55AM	Fidelity Select Health Care Portfolio Q1 2025 Commentary (Seeking Alpha)
May-06-25 06:20AM	Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now? (Zacks)
May-05-25 10:00AM	Fidelity OTC Portfolio Q1 2025 Commentary (Seeking Alpha) +5.46%
10:00AM	Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference (Business Wire)
May-02-25 10:51AM	Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y (Zacks)
03:05AM	Alnylam Pharmaceuticals Inc (ALNY) Q1 2025 Earnings Call Highlights: Robust Revenue Growth and ... (GuruFocus.com)
12:29AM	Loading…
12:29AM	Q1 2025 Alnylam Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-01-25 10:46PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
01:11PM	Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript (Seeking Alpha)
10:30AM	Compared to Estimates, Alnylam (ALNY) Q1 Earnings: A Look at Key Metrics (Zacks)
09:20AM	Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:22AM	Alnylam: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress (Business Wire)
Apr-30-25 08:02PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
05:15PM	MiMedx (MDXG) Q1 Earnings Match Estimates (Zacks)
04:27PM	BridgeBio Breaks Out After Pfizer-Rivaling Heart Drug Obliterates Sales Expectations (Investor's Business Daily)
Apr-29-25 04:01PM	BridgeBio's Pfizer-Rivaling Heart Drug Just Obliterated Sales Expectations (Investor's Business Daily)
09:15AM	Seeking Clues to Alnylam (ALNY) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics (Zacks)
Apr-28-25 10:00AM	Earnings Preview: Axsome Therapeutics (AXSM) Q1 Earnings Expected to Decline (Zacks)
08:00AM	Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy (Business Wire)
Apr-24-25 10:01AM	Earnings Preview: Alnylam Pharmaceuticals (ALNY) Q1 Earnings Expected to Decline (Zacks)
08:00AM	Loading…
Apr-17-25 08:00AM	Alnylam to Webcast Conference Call Discussing First Quarter 2025 Financial Results (Business Wire)
Apr-14-25 02:03PM	Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Growth Stock to Buy According to Billionaires? (Insider Monkey)
Apr-11-25 05:30AM	How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs (The Wall Street Journal) +5.08%
Apr-10-25 09:32AM	Alnylam (ALNY) Moves 8.5% Higher: Will This Strength Last? (Zacks) -6.98%
06:18AM	Seeking Recession-Proof Stocks? RBC Suggests 2 Healthcare Stocks to Buy (TipRanks)
Apr-08-25 02:08PM	Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Long Term Growth Stock to Buy According to Billionaires? (Insider Monkey)
Apr-04-25 08:04PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) -10.08%
04:54PM	Top Analyst Reports for Broadcom, UnitedHealth & Toyota Motor (Zacks)
Apr-02-25 06:20AM	Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar? (Zacks)
Apr-01-25 09:44AM	SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States (Zacks) -5.28%
08:00AM	Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference (Business Wire)
Mar-29-25 01:00PM	Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology's Annual Scientific Session 2025 (Business Wire)
Mar-28-25 04:44PM	FDA Approves Qfitlia (fitusiran), the First siRNA (RNAi Therapeutic) for the Treatment of Hemophilia A or B (Business Wire)
11:30AM	Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound? (Zacks)
09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
06:24AM	Intellia: Nex-Z Advancement Remains On Track With Expanded ATTRv-PN Indication (Seeking Alpha)
Mar-27-25 11:30AM	Jazz (JAZZ) Down 9.2% Since Last Earnings Report: Can It Rebound? (Zacks)
Mar-26-25 10:02AM	Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & More (Zacks)
Mar-25-25 07:28AM	Verve Therapeutics: HeFH Treatment Program Of VERVE-102 Remains On Track With 2025 Catalysts (SeekingAlpha)
Mar-24-25 09:57AM	Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? (Zacks)
Mar-22-25 09:40AM	Alnylam price target raised to $338 from $300 at Scotiabank (TipRanks)
Mar-21-25 07:13PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +11.75%
05:37PM	Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster (SeekingAlpha)
04:13PM	Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio (Investor's Business Daily)
02:04PM	Alnylam challenges Pfizer and BridgeBio with FDA nod for ATTR-CM drug (Pharmaceutical Technology)
01:21PM	Alnylam Stock Jumps After the FDA Approves Its Heart Drug (The Wall Street Journal)
12:46PM	Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy (Zacks)
11:30AM	BioMarin (BMRN) Up 4.2% Since Last Earnings Report: Can It Continue? (Zacks)
10:05AM	Alnylam Heart Drug Approval Sets Up Challenge With Pfizer (Bloomberg)
07:37AM	Alnylam prices heart drug at premium to rivals (BioPharma Dive)
Mar-20-25 06:13PM	Alnylam nabs key additional indication for Amvuttra (SeekingAlpha)
05:54PM	Alnylam Announces FDA Approval of AMVUTTRA (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) (Business Wire)
01:57PM	Alnylam drug gets long-awaited FDA approval in deadly heart disease (BioPharma Dive)
Mar-11-25 08:00AM	Alnylam to Webcast Presentation at Stifel 2025 Virtual CNS Forum (Business Wire)
Mar-05-25 07:00AM	Alnylam Announces Retirement of Longtime Board Member, Dr. Phillip A. Sharp, Company Co-Founder and Industry Luminary (Business Wire)
Feb-27-25 01:30PM	Q4 2024 Vir Biotechnology Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-25-25 07:00AM	Alnylam Highlights Significant Pipeline Progress and Platform Innovation at R&D Day (Business Wire)
Feb-24-25 07:11PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
12:59PM	Alnylam Pharmaceuticals (ALNY): Among the Oversold Biotech Stocks to Buy Now (Insider Monkey)
Feb-14-25 04:35PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)
02:10AM	Alnylam Pharmaceuticals Inc (ALNY) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Feb-13-25 11:26PM	Q4 2024 Alnylam Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
09:30AM	Alnylam (ALNY) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
09:15AM	Alnylam Pharmaceuticals (ALNY) Beats Q4 Earnings and Revenue Estimates (Zacks)
08:18AM	Alnylam: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Period Progress (Business Wire)
Feb-10-25 09:16AM	Ahead of Alnylam (ALNY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics (Zacks)
Feb-06-25 10:01AM	Alnylam Pharmaceuticals (ALNY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Jan-30-25 08:00AM	Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Jan-23-25 09:50AM	Here's Why Alnylam Pharmaceuticals (ALNY) is a Strong Momentum Stock (Zacks)
Jan-21-25 07:20PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) +7.60%
09:40AM	Are Medical Stocks Lagging Alnylam Pharmaceuticals (ALNY) This Year? (Zacks)
Jan-12-25 04:00PM	Alnylam Announces Preliminary* Fourth Quarter and Full Year 2024 Global Net Product Revenues and Provides 2025 Combined Net Product Revenue Guidance and Pipeline Goals (Business Wire)
Jan-06-25 08:00AM	Alnylam to Webcast Presentation at 43rd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-25-24 09:40AM	Is Alnylam Pharmaceuticals (ALNY) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-23-24 10:09AM	Is Alnylam Pharmaceuticals, Inc. (ALNY) the Best Performing Biotech Stock in 2024? (Insider Monkey)
Dec-04-24 12:00PM	What Makes Alnylam (ALNY) a New Buy Stock (Zacks)
Dec-02-24 02:48PM	Why Is Alnylam Pharmaceuticals, Inc. (ALNY) Among the Best High Growth Healthcare Stocks to Invest In Now? (Insider Monkey)
Nov-27-24 07:00AM	Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference (Business Wire)
05:38AM	Kronos, Idorsia plan layoffs; PTC shelves ALS drug (BioPharma Dive)
Nov-25-24 04:16PM	BridgeBio Catapults After Snagging Approval For Its Rival To Pfizer's Heart Drug (Investor's Business Daily)
07:00AM	Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy (Business Wire)
Nov-22-24 02:16PM	BridgeBio heart drug approved by FDA, setting up battle with Pfizer (BioPharma Dive)
Nov-18-24 07:24AM	Alnylam reveals trial outcomes of nucresiran for ATTR amyloidosis treatment (Clinical Trials Arena)
Nov-17-24 09:30AM	Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose (Business Wire)
Nov-15-24 07:19PM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research) -8.67%
Nov-06-24 12:26PM	Top 20 biopharmas market cap rises 2% in Q3 2024 amid flurry of drug approvals (Pharmaceutical Technology)
04:27AM	An RNAi renaissance is creating a new generation of startups (BioPharma Dive)
Nov-04-24 08:00AM	Alnylam to Webcast Presentations at Upcoming November Investor Conferences (Business Wire)
Nov-01-24 10:34AM	Analyst Report: Alnylam Pharmaceuticals, Inc. (Morningstar Research)

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company was founded by Noble Laureate, David Bartel, Thomas Tuschl, Phillip Zamore, Paul R. Schimmel, and Phillip Allen Sharp on June 14, 2002 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BONNEY MICHAEL W	Director	May 15 '25	Option Exercise	131.21	11,250	1,476,112	28,054	May 19 04:17 PM
BONNEY MICHAEL W	Director	May 15 '25	Sale	277.71	11,250	3,124,217	16,804	May 19 04:17 PM
BONNEY MICHAEL W	Director	May 15 '25	Proposed Sale	269.53	11,250	3,032,212		May 15 04:03 PM
Reitan Colleen F	Director	Aug 29 '24	Buy	286.00	32	9,152	32	May 12 04:05 PM
Reitan Colleen F	Director	Oct 17 '24	Buy	302.67	4	1,211	36	May 12 04:05 PM
Reitan Colleen F	Director	Apr 16 '25	Sale	232.86	36	8,383	0	May 12 04:05 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 24 '25	Option Exercise	42.22	5,445	229,888	25,666	Mar 25 04:10 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 24 '25	Sale	300.00	5,445	1,633,500	20,221	Mar 25 04:10 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 21 '25	Sale	285.00	4,321	1,231,485	20,221	Mar 25 04:10 PM
PYOTT DAVID E I	Director	Mar 24 '25	Option Exercise	88.95	7,440	661,788	7,576	Mar 25 04:09 PM
PYOTT DAVID E I	Director	Mar 24 '25	Sale	299.00	7,440	2,224,560	136	Mar 25 04:09 PM
PYOTT DAVID E I	Director	Mar 24 '25	Proposed Sale	299.00	7,440	2,224,560		Mar 24 04:13 PM
Garg Pushkal	Officer	Mar 24 '25	Proposed Sale	300.00	5,445	1,633,500		Mar 24 04:06 PM
Garg Pushkal	Officer	Mar 21 '25	Proposed Sale	285.00	4,321	1,231,485		Mar 21 04:03 PM
SCHULMAN AMY W	Director	Mar 13 '25	Option Exercise	131.21	2,750	360,828	11,186	Mar 14 04:16 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 03 '25	Sale	243.73	1,911	465,772	14,345	Mar 05 04:22 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Mar 04 '25	Sale	241.15	844	203,532	13,501	Mar 05 04:22 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Mar 03 '25	Sale	243.78	471	114,820	28,011	Mar 05 04:22 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 03 '25	Sale	243.79	1,749	426,384	25,350	Mar 05 04:21 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Mar 04 '25	Sale	241.05	808	194,766	24,542	Mar 05 04:21 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Mar 03 '25	Sale	243.78	1,264	308,141	47,751	Mar 05 04:21 PM
Greenstreet Yvonne	Chief Executive Officer	Mar 03 '25	Sale	243.79	3,877	945,165	98,635	Mar 05 04:20 PM
Fitzgerald Kevin Joseph	Officer	Mar 04 '25	Proposed Sale	241.09	844	203,479		Mar 04 04:07 PM
Garg Pushkal	Officer	Mar 04 '25	Proposed Sale	241.09	808	194,801		Mar 04 04:06 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 27 '25	Option Exercise	0.00	5,921	0	87,447	Mar 03 04:32 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 28 '25	Sale	241.69	2,900	700,894	84,547	Mar 03 04:32 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 27 '25	Option Exercise	0.00	1,908	0	34,694	Mar 03 04:31 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 28 '25	Sale	241.70	796	192,390	33,898	Mar 03 04:31 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 27 '25	Option Exercise	0.00	1,667	0	14,858	Mar 03 04:31 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Feb 28 '25	Sale	241.68	513	123,983	14,345	Mar 03 04:31 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 27 '25	Option Exercise	0.00	1,908	0	13,897	Mar 03 04:31 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 28 '25	Sale	241.69	935	225,977	12,962	Mar 03 04:31 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 28 '25	Sale	241.69	496	119,878	12,385	Mar 03 04:30 PM
Garg Pushkal	Officer	Mar 03 '25	Proposed Sale	246.18	973	239,533		Mar 03 04:09 PM
Fitzgerald Kevin Joseph	Officer	Mar 03 '25	Proposed Sale	246.18	1,171	288,277		Mar 03 04:09 PM
Greenstreet Yvonne	Chief Executive Officer	Feb 14 '25	Sale	255.17	1,213	309,527	81,526	Feb 18 04:49 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Feb 14 '25	Sale	255.17	967	246,750	32,786	Feb 18 04:47 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 18 '25	Sale	251.56	1,440	362,243	12,881	Feb 18 04:47 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Feb 14 '25	Sale	255.21	663	169,204	14,321	Feb 18 04:47 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 14 '25	Sale	255.17	1,561	398,325	13,537	Feb 18 04:47 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Feb 18 '25	Sale	251.67	1,548	389,579	11,989	Feb 18 04:47 PM
Garg Pushkal	Officer	Feb 18 '25	Proposed Sale	256.95	1,548	397,759		Feb 18 04:14 PM
Fitzgerald Kevin Joseph	Officer	Feb 18 '25	Proposed Sale	256.95	1,440	370,008		Feb 18 04:13 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Jan 27 '25	Option Exercise	88.95	48,876	4,347,520	64,581	Jan 29 04:03 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Jan 27 '25	Sale	285.00	52,592	14,988,720	11,989	Jan 29 04:03 PM
Garg Pushkal	Officer	Jan 27 '25	Proposed Sale	285.00	52,592	14,988,720		Jan 27 04:01 PM
SHARP PHILLIP A	Director	Jan 23 '25	Option Exercise	131.21	11,250	1,476,112	11,250	Jan 24 04:10 PM
SHARP PHILLIP A	Director	Jan 23 '25	Sale	275.00	11,250	3,093,750	0	Jan 24 04:10 PM
SHARP PHILLIP A	Director	Jan 23 '25	Proposed Sale	275.00	11,250	3,093,750		Jan 23 04:17 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Dec 12 '24	Sale	251.00	1,752	439,760	15,705	Dec 13 04:13 PM
Garg Pushkal	Officer	Dec 12 '24	Proposed Sale	255.02	1,752	446,795		Dec 12 04:05 PM
Greenstreet Yvonne	Chief Executive Officer	Nov 26 '24	Sale	250.98	5,219	1,309,853	78,880	Nov 27 05:22 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Nov 26 '24	Sale	250.98	1,682	422,144	17,457	Nov 27 05:22 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Nov 26 '24	Sale	250.98	1,682	422,144	30,644	Nov 27 05:21 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Nov 26 '24	Sale	250.98	1,469	368,686	13,191	Nov 27 05:21 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 27 '24	Sale	252.29	1,531	386,261	12,881	Nov 27 05:20 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Nov 26 '24	Sale	250.98	1,469	368,686	14,412	Nov 27 05:20 PM
Fitzgerald Kevin Joseph	Officer	Nov 27 '24	Proposed Sale	253.98	1,531	388,843		Nov 27 04:06 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 20 '24	Option Exercise	85.00	15,000	1,275,000	88,441	Aug 22 08:01 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 20 '24	Sale	280.00	15,000	4,200,000	73,441	Aug 22 08:01 PM
Greenstreet Yvonne	Officer	Aug 20 '24	Proposed Sale	280.00	15,000	4,200,000		Aug 20 05:10 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 12 '24	Option Exercise	89.09	20,725	1,846,429	34,906	Aug 14 04:12 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Aug 12 '24	Sale	270.99	22,025	5,968,516	12,881	Aug 14 04:12 PM
Fitzgerald Kevin Joseph	Officer	Aug 12 '24	Proposed Sale	269.52	22,025	5,936,178		Aug 12 04:07 PM
Ausiello Dennis A	Director	Aug 06 '24	Option Exercise	119.68	20,250	2,423,452	20,386	Aug 08 04:10 PM
Ausiello Dennis A	Director	Aug 06 '24	Sale	262.00	20,250	5,305,586	136	Aug 08 04:10 PM
Ausiello Dennis A	Director	Aug 06 '24	Proposed Sale	266.66	20,250	5,399,865		Aug 06 04:07 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 01 '24	Option Exercise	85.00	15,148	1,287,580	88,589	Aug 02 08:01 PM
Greenstreet Yvonne	Chief Executive Officer	Aug 01 '24	Sale	270.00	15,148	4,089,960	73,441	Aug 02 08:01 PM
Greenstreet Yvonne	Officer	Aug 01 '24	Proposed Sale	270.00	15,148	4,089,960		Aug 01 04:01 PM
Greenstreet Yvonne	Chief Executive Officer	Jul 11 '24	Sale	261.00	7,093	1,851,273	73,441	Jul 12 08:02 PM
SCHULMAN AMY W	Director	Jun 25 '24	Option Exercise	131.21	8,500	1,115,285	16,936	Jun 27 04:04 PM
SCHULMAN AMY W	Director	Jun 25 '24	Sale	240.00	8,500	2,040,000	8,436	Jun 27 04:04 PM
PYOTT DAVID E I	Director	Jun 24 '24	Option Exercise	80.76	32,450	2,620,611	32,586	Jun 26 04:28 PM
PYOTT DAVID E I	Director	Jun 24 '24	Sale	220.69	32,450	7,161,360	136	Jun 26 04:28 PM
Garg Pushkal	CMO & EVP Dev & Med Affairs	Jun 25 '24	Sale	230.99	2,103	485,773	15,609	Jun 26 04:28 PM
Greenstreet Yvonne	Chief Executive Officer	Jun 25 '24	Sale	230.99	8,301	1,917,475	80,534	Jun 26 04:27 PM
Poulton Jeffrey V.	EVP, Chief Financial Officer	Jun 25 '24	Sale	231.00	1,605	370,747	28,892	Jun 26 04:26 PM
Tanguler Tolga	EVP, Chief Commercial Officer	Jun 25 '24	Sale	231.00	1,605	370,747	11,660	Jun 26 04:26 PM
Fitzgerald Kevin Joseph	CSO & EVP, Head of Research	Jun 25 '24	Sale	230.99	1,198	276,731	14,181	Jun 26 04:26 PM
SCHULMAN AMY W	Director	May 29 '24	Option Exercise	66.83	30,000	2,004,900	30,136	May 31 07:00 PM
SCHULMAN AMY W	Director	May 29 '24	Sale	148.60	21,700	3,224,546	8,436	May 31 07:00 PM

Dollar change -0.14
Percentage change -3.44	%

MYGN Myriad Genetics, Inc daily Stock Chart

Peers: ILMN GH INCY QGEN EXAS NTLA CRSP CDNA TXG TWST

| Held by: IJR VTI VB VXF VBR IWM XBI IJS IWN VTWO

Index	RUT	P/E	-	EPS (ttm)	-1.12	Insider Own	4.81%	Shs Outstand	92.20M	Perf Week	-4.38%
Market Cap	362.26M	Forward P/E	25.19	EPS next Y	0.16	Insider Trans	0.00%	Shs Float	87.74M	Perf Month	-46.09%
Income	-101.40M	PEG	-	EPS next Q	-0.01	Inst Own	102.42%	Short Float	6.37%	Perf Quarter	-72.28%
Sales	831.30M	P/S	0.44	EPS this Y	-106.15%	Inst Trans	0.27%	Short Ratio	2.91	Perf Half Y	-74.18%
Book/sh	7.65	P/B	0.51	EPS next Y	1913.51%	ROA	-9.58%	Short Interest	5.59M	Perf Year	-84.29%
Cash/sh	1.00	P/C	3.95	EPS next 5Y	26.55%	ROE	-13.84%	52W Range	3.81 - 29.30	Perf YTD	-71.33%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-11.91%	52W High	-86.59%	Beta	1.89
Dividend TTM	-	Quick Ratio	1.71	Sales past 5Y	6.82%	Gross Margin	67.47%	52W Low	3.10%	ATR (14)	0.46
Dividend Ex-Date	-	Current Ratio	1.90	EPS Y/Y TTM	60.45%	Oper. Margin	-10.72%	RSI (14)	27.03	Volatility	6.71% 12.81%
Employees	2700	Debt/Eq	0.22	Sales Y/Y TTM	7.38%	Profit Margin	-12.20%	Recom	3.00	Target Price	7.40
Option/Short	Yes / Yes	LT Debt/Eq	0.21	EPS Q/Q	99.62%	Payout	-	Rel Volume	1.21	Prev Close	4.07
Sales Surprise	-2.32%	EPS Surprise	44.95%	Sales Q/Q	-3.12%	Earnings	May 06 AMC	Avg Volume	1.92M	Price	3.93
SMA20	-27.69%	SMA50	-46.85%	SMA200	-75.56%	Trades		Volume	2,314,109	Change	-3.44%

Date	Action	Analyst	Rating Change	Price Target Change
May-21-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$6
May-08-25	Downgrade	Wolfe Research	Outperform → Peer Perform
May-07-25	Downgrade	Wells Fargo	Overweight → Equal Weight	$6
Apr-09-25	Downgrade	Guggenheim	Buy → Neutral
Mar-12-25	Upgrade	Piper Sandler	Neutral → Overweight	$11.50 → $12.50
Feb-12-25	Initiated	Craig Hallum	Buy	$29
Dec-10-24	Initiated	UBS	Neutral	$18
Dec-09-24	Downgrade	Leerink Partners	Outperform → Market Perform	$30 → $21
Sep-19-24	Initiated	Morgan Stanley	Equal-Weight	$32
Aug-28-24	Initiated	Wells Fargo	Overweight	$35
Jun-27-24	Initiated	Scotiabank	Sector Outperform	$29
Jun-03-24	Resumed	Jefferies	Underperform	$20
May-08-24	Upgrade	Leerink Partners	Market Perform → Outperform	$25 → $35
Dec-21-23	Resumed	Piper Sandler	Neutral	$23
Dec-19-23	Initiated	Wells Fargo	Equal Weight	$20
Dec-14-23	Initiated	Guggenheim	Buy	$23
Dec-13-23	Initiated	Wolfe Research	Outperform	$28
Jul-05-23	Resumed	JP Morgan	Underweight	$18
May-23-23	Upgrade	Goldman	Sell → Buy	$18 → $25
Jan-18-23	Upgrade	Raymond James	Mkt Perform → Outperform	$25

Show Previous Ratings

May-19-25 09:58AM	MYGN Q1 Earnings Call: Guidance Cut Amid GeneSight Challenges and Slow Hereditary Cancer Ramp (StockStory) +7.26%
May-14-25 04:45PM	Updated: Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences (GlobeNewswire) -6.57% +7.03%
May-09-25 04:07AM	Myriad Genetics, Inc. (MYGN): Among Billionaire Larry Robbins' Stock Picks with Huge Upside Potential (Insider Monkey)
May-08-25 09:35AM	Down -49.47% in 4 Weeks, Here's Why Myriad (MYGN) Looks Ripe for a Turnaround (Zacks) -5.62%
May-07-25 04:30PM	Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology (GlobeNewswire) -41.27%
08:34AM	Loading…
08:34AM	MYGN Q1 Earnings Top Estimates, Stock Down on Weak 2025 Outlook (Zacks)
03:19AM	Myriad Genetics Inc (MYGN) Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and ... (GuruFocus.com)
May-06-25 11:35PM	Myriad genetics lowers 2025 revenue guidance by $35M amid GeneSight challenges (Seeking Alpha) -5.58%
11:35PM	Myriad Genetics, Inc. (MYGN) Q1 2025 Earnings Call Transcript (Seeking Alpha)
07:30PM	Myriad (MYGN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:35PM	Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance (GlobeNewswire)
May-02-25 12:58AM	Myriad Genetics: Significantly Undervalued With Profitability In Sight (Seeking Alpha) +6.03%
12:39AM	3 Unprofitable Stocks Walking a Fine Line (StockStory)
May-01-25 12:34AM	1 Unprofitable Stock to Target This Week and 2 to Be Wary Of (StockStory)
08:00AM	Loading…
Apr-30-25 08:00AM	Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor (GlobeNewswire)
Apr-29-25 09:00AM	Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025 (GlobeNewswire)
Apr-25-25 04:05PM	Myriad Genetics Highlights MRD Clinical Validity Data at American Association for Cancer Research Annual Meeting (GlobeNewswire)
09:16AM	3 Healthcare Stocks That Concern Us (StockStory)
Apr-22-25 10:10AM	Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside? (Zacks)
Apr-21-25 04:05PM	Myriad Genetics Announces Study Results Show Patients with Depression had Fewer Psychiatric Hospitalizations after GeneSight Testing (GlobeNewswire)
Apr-15-25 10:02AM	Myriad Genetics price target lowered to $9 from $11 at BofA (TipRanks)
Apr-08-25 04:15PM	Myriad Genetics Announces Inducement Awards (GlobeNewswire) +9.31%
Apr-07-25 08:00AM	Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer (GlobeNewswire)
Mar-28-25 08:56AM	Is Myriad Genetics Stock Worth Holding in Your Portfolio Now? (Zacks)
Mar-26-25 11:30AM	Myriad (MYGN) Down 17.1% Since Last Earnings Report: Can It Rebound? (Zacks) -5.34%
Mar-25-25 10:45AM	Allspring Small Company Growth Fund Q4 2024 Commentary (SeekingAlpha)
Mar-21-25 08:30AM	Artisan International Small-Mid Fund Q4 2024 Commentary (SeekingAlpha)
Mar-19-25 05:05AM	A Look Back at Therapeutics Stocks Q4 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) Vs The Rest Of The Pack (StockStory)
Mar-17-25 05:10AM	Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q4 Earnings? (StockStory)
01:17PM	Loading…
Mar-12-25 01:17PM	Why Are Myriad Genetics (MYGN) Shares Soaring Today (StockStory)
Mar-11-25 05:03AM	Winners And Losers Of Q4: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks (StockStory) +6.77%
Mar-04-25 04:03AM	Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4 (StockStory)
Feb-27-25 04:15PM	Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools (GlobeNewswire)
Feb-25-25 02:07PM	Why Myriad Genetics (MYGN) Shares Are Plunging Today (StockStory) -14.80%
10:25AM	Myriad Genetics, Inc. (MYGN): AI-Driven Precision Medicine for Prostate Cancer (Insider Monkey)
07:59AM	Q4 2024 Myriad Genetics Inc Earnings Call (Thomson Reuters StreetEvents)
02:03AM	Myriad Genetics Inc (MYGN) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
Feb-24-25 07:00PM	Myriad (MYGN) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
06:00PM	Myriad Genetics (MYGN) Meets Q4 Earnings Estimates (Zacks)
05:11PM	Myriad: Q4 Earnings Snapshot (Associated Press Finance)
04:31PM	Myriad Genetics (NASDAQ:MYGN) Misses Q4 Sales Targets, Stock Drops (StockStory)
04:05PM	Myriad Genetics Reports Fourth Quarter and Full-Year 2024 Financial Results; Full-year 2024 revenue of $838 million grew 11% year-over-year, the second consecutive year of double-digit revenue growth (GlobeNewswire)
04:05PM	Myriad Genetics Announces Senior Leadership Transition (GlobeNewswire)
08:30AM	Myriad Genetics Partners with PATHOMIQ to add Artificial Intelligence Technology Platform to its Oncology Portfolio (GlobeNewswire)
Feb-23-25 08:01AM	What To Expect From Myriad Geneticss (MYGN) Q4 Earnings (StockStory)
Feb-19-25 08:30AM	Myriad Genetics Included in Forbes America's Best Employers 2025 List (GlobeNewswire)
Feb-18-25 08:30AM	Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025 (GlobeNewswire)
Feb-17-25 06:05AM	3 Reasons to Sell MYGN and 1 Stock to Buy Instead (StockStory)
Feb-06-25 08:30AM	Myriad Genetics and CancerCARE for Life Announce Agreement to Advance Access to MyRisk with RiskScore Hereditary Cancer Test (GlobeNewswire)
Feb-05-25 04:15PM	Myriad Genetics Announces Two New Patents Granted for its Molecular Residual Disease (MRD) Assay (GlobeNewswire)
08:30AM	Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration (GlobeNewswire)
Jan-29-25 08:30AM	Myriad Genetics Unveils Groundbreaking Eight Weeks' Gestation NIPT Study Results at Society for Maternal-Fetal Medicine Conference (GlobeNewswire)
Jan-24-25 08:08PM	Why Is Larry Robbins Bullish on Myriad Genetics, Inc. (MYGN) Now? (Insider Monkey)
Jan-23-25 08:30AM	Myriad Genetics Introduces Online Prenatal Genetic Testing Resource (GlobeNewswire)
Jan-21-25 08:30AM	Myriad Genetics Announces Hereditary Cancer Risk Assessment Program Study Published in Obstetrics & Gynecology (GlobeNewswire)
Jan-15-25 08:30AM	Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2024 Financial Results and Introduces Full Year 2025 Financial Guidance (GlobeNewswire)
Jan-09-25 04:30PM	Myriad Genetics Signs Agreement with Nationally Renowned Sports Broadcaster Hannah Storm to Promote the Importance of Knowing Family Cancer History (GlobeNewswire)
Jan-08-25 11:27AM	UPDATE Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
08:00AM	Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-07-25 08:00AM	MD Anderson and Myriad Genetics form strategic alliance to evaluate clinical utility of Myriad's molecular residual disease assay (GlobeNewswire)
Jan-06-25 08:00AM	Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report (GlobeNewswire)
Dec-19-24 04:15PM	Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics (GlobeNewswire)
Dec-10-24 06:26PM	Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing (GlobeNewswire) -5.41%
04:05PM	Myriad Genetics Expands Board of Directors with Election of Mark S. Davis as New Board Member (GlobeNewswire)
08:00AM	Myriad Genetics' Portfolio Elevated by Updated NCCN Prostate Cancer Guidelines (GlobeNewswire)
Dec-09-24 04:05PM	Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium (GlobeNewswire)
08:00AM	NCCN Prostate Cancer Guidelines Reinforce Status of Myriad Genetics' Prolaris Test as an 'Advanced Tool' Recommended for Prognostic Assessment (GlobeNewswire)
Nov-20-24 04:30PM	Myriad Genetics Announces Incorporation of its Proprietary HRD platform in Illumina's Updated Comprehensive Gene Panel Assay, TruSight Oncology 500 v2 (GlobeNewswire)
Nov-19-24 08:00AM	Myriad Genetics Announces Prequel Prenatal Screening Can Now be Performed Eight Weeks into Pregnancy (GlobeNewswire)
07:27AM	Myriad Genetics price target lowered to $21 from $32 at Morgan Stanley (TipRanks)
Nov-13-24 08:00AM	Myriad Genetics Expands Access to At-Home Early Fetal Sex DNA Test with Retail Launch (GlobeNewswire)
Nov-08-24 02:26AM	Myriad Genetics Inc (MYGN) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid Policy ... (GuruFocus.com)
Nov-07-24 06:30PM	Compared to Estimates, Myriad (MYGN) Q3 Earnings: A Look at Key Metrics (Zacks)
06:00PM	Myriad Genetics (MYGN) Q3 Earnings and Revenues Surpass Estimates (Zacks)
05:02PM	Myriad: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance (GlobeNewswire)
Nov-04-24 08:39AM	Myriad Genetics Comments on UnitedHealthcare's Updated Medical Policy for Pharmacogenetic Testing (GlobeNewswire)
Nov-02-24 11:15AM	Myriad weakness due to UnitedHealth coverage update, says Stephens (TipRanks)
Nov-01-24 06:55PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research) -18.08%
Oct-30-24 08:00AM	Myriad Genetics to Release Third Quarter 2024 Financial Results on November 7, 2024 (GlobeNewswire)
Oct-28-24 10:01AM	Myriad Genetics (MYGN) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-22-24 02:19PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Oct-16-24 09:00AM	Myriad Genetics and jscreen Announce Strategic Partnership to Advance Health Equity and Genetic Testing Access (GlobeNewswire)
Oct-15-24 09:00AM	Myriad Genetics and Flatiron Health Partner to Make Genetic Testing More Accessible with Electronic Medical Record Integration (GlobeNewswire)
Oct-09-24 07:49AM	Myriad signs five partnerships to study MRD testing in breast cancer (Clinical Trials Arena) -6.12%
Oct-08-24 04:05PM	Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer (GlobeNewswire)
Oct-04-24 06:33AM	Myriad and Ultima to study UG 100 sequencing platform for genomics clinical tests (Medical Device Network)
Oct-03-24 09:00AM	Myriad Genetics and Ultima Genomics to Explore the UG 100 Sequencing Platform to Advance Clinical Test Offerings in Oncology and Reproductive Genomics (GlobeNewswire)
Oct-01-24 04:05PM	Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date (GlobeNewswire)
Sep-25-24 06:38PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Sep-18-24 09:50AM	Here's Why Myriad Genetics (MYGN) is a Strong Momentum Stock (Zacks)
08:00AM	Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference (GlobeNewswire)
Sep-16-24 06:37PM	Analyst Report: Myriad Genetics, Inc. (Morningstar Research)
Sep-13-24 01:54AM	Insider Sale: Chief Scientific Officer Dale Muzzey Sells Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
01:54AM	Insider Sale: President and CEO Paul Diaz Sells 15,000 Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
Sep-10-24 01:17AM	Insider Sale: Director Heinrich Dreismann Sells Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)
Sep-05-24 11:31AM	Myriad (MYGN) Down 4.8% Since Last Earnings Report: Can It Rebound? (Zacks) +9.07%
08:00AM	Myriad Genetics to Host Investor Event on October 9, 2024 (GlobeNewswire)
01:33AM	Insider Sale: Director Colleen Reitan Sells Shares of Myriad Genetics Inc (MYGN) (GuruFocus.com)

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
DIAZ PAUL J	President and CEO	Oct 11 '24	Sale	22.93	15,000	343,950	962,378	Oct 11 05:23 PM
DIAZ PAUL J	Officer	Oct 11 '24	Proposed Sale	22.93	15,000	343,950		Oct 11 10:35 AM
Ancona Margaret	Officer	Aug 21 '24	Proposed Sale	27.82	11,538	321,019		Sep 16 02:30 PM
DIAZ PAUL J	President and CEO	Sep 11 '24	Sale	26.72	15,000	400,800	977,378	Sep 12 04:11 PM
Muzzey Dale	Chief Scientific Officer	Sep 11 '24	Sale	26.17	2,100	54,961	108,013	Sep 12 04:09 PM
Muzzey Dale	Officer	Sep 11 '24	Proposed Sale	26.17	2,100	54,961		Sep 11 03:26 PM
DIAZ PAUL J	Officer	Sep 11 '24	Proposed Sale	26.72	15,000	400,800		Sep 11 10:05 AM
Dreismann Heinrich	Director	Sep 09 '24	Sale	27.05	10,000	270,520	121,648	Sep 09 05:48 PM
Dreismann Heinrich	Director	Sep 10 '24	Proposed Sale	27.00	10,000	270,000		Sep 09 02:52 PM
Reitan Colleen F	Director	Sep 03 '24	Sale	27.95	46,012	1,285,851	42,533	Sep 04 07:38 PM
Reitan Colleen F	Director	Sep 03 '24	Proposed Sale	28.19	46,012	1,297,078		Sep 03 10:11 AM
Ancona Margaret	SVP, Chief of Staff	Aug 21 '24	Sale	27.82	11,538	320,987	79,366	Aug 23 04:16 PM
Kumar Rashmi	Director	Aug 19 '24	Sale	28.01	7,500	210,075	77,392	Aug 20 04:38 PM
Kumar Rashmi	Director	Aug 19 '24	Proposed Sale	28.01	7,500	210,075		Aug 19 02:46 PM
SPIEGELMAN DANIEL K	Director	Jun 04 '24	Sale	22.05	3,788	83,525	32,917	Jun 04 05:57 PM
SPIEGELMAN DANIEL K	Director	Jun 03 '24	Sale	22.04	3,788	83,488	36,705	Jun 04 05:57 PM

ALNY

Alnylam Pharmaceuticals Inc

MYGN

Myriad Genetics, Inc

Upgrade your FINVIZ experience